A supplemental Biologics License Application has been submitted to the FDA for Anktiva plus BCG in papillary NMIBC.

During a live event, Matthew Galsky, MD, discussed adjuvant nivolumab in muscle-invasive bladder cancer and the benefit in ...

The investigational therapy combines mRNA technology with immunotherapy to train the immune system to target cancer cells ...

Citation: Second TB vaccination boosts immunity in bladder cancer patients and reduces cancer recurrence, pilot study suggests (2025, March 22) retrieved 14 April 2025 from https://medicalxpress ...

"Bladder cancer is a common cancer ... and change the way you need to pee—in the most severe cases, it may involve the removal of your bladder, prostate, lymph nodes and urethra.

Erdafitinib, also known as Balversa and made by Johnson & Johnson, is recommended in final draft guidance for adults with metastatic or unresectable FGFR-altered urothelial cancer who have previously ...

The ability to accurately anticipate how an individual will react to the standard-of-care therapy for this malignant cancer may help ... well from undergoing bladder removal.

AstraZeneca (AZ) has announced that its Imfinzi (durvalumab) perioperative regimen has been approved by the US Food and Drug Administration (FDA) to treat adults with muscle-invasive bladder cancer ...

Health disparities lead to delayed diagnosis of these seven cancer types in the Black community, but awareness and early screening can help save lives.

In Q1, the company submitted a supplemental Biologics License Application (sBLA) for use of ANKTIVA® plus Bacillus Calmette-Guérin (BCG) in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) ...

Meri-Margaret Deoudes, CEO of the Bladder Cancer Advocacy Network, said: "More than 20,000 people in the US were treated for muscle-invasive bladder cancer last year and there is a significant ...